


PHARMACEUTICAL 2022

Vallon Pharmaceuticals Inc. Rank 429 of 475





PHARMACEUTICAL 2022

Vallon Pharmaceuticals Inc. Rank 429 of 475

The relative strengths and weaknesses of Vallon Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Vallon Pharmaceuticals Inc. compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 49% points. The greatest weakness of Vallon Pharmaceuticals Inc. is the variable Net Income, reducing the Economic Capital Ratio by 343% points.

The company's Economic Capital Ratio, given in the ranking table, is -578%, being 302% points below the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	8,129
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	2,445
Liabilities, Non-Current	72
Other Assets	206
Other Compr. Net Income	-2.0
Other Expenses	0
Other Liabilities	0
Other Net Income	-44
Property and Equipment	0
Research and Development	5,187
Revenues	0
Selling, General and Administrative Expense	4,072

Output Variable	Value in 1000 USD
Assets	8,335
Liabilities	2,517
Expenses	9,259
Stockholders Equity	5,818
Net Income	-9,303
Comprehensive Net Income	-9,304
Economic Capital Ratio	-578%